943995-32-2

Basic information

• Product Name: 2-chloro-6H,7H,8H-pyrimido [5,4-b][1,4]oxazin-7-one
• Synonyms: 2-chloro-6H,7H,8H-pyrimido [5,4-b][1,4]oxazin-7-one
• CAS NO: 943995-32-2
• Molecular Weight: 185.57
• Mol File: 943995-32-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-chloro-6H,7H,8H-pyrimido [5,4-b][1,4]oxazin-7-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-6H,7H,8H-pyrimido [5,4-b][1,4]oxazin-7-one(943995-32-2)
• EPA Substance Registry System: 2-chloro-6H,7H,8H-pyrimido [5,4-b][1,4]oxazin-7-one(943995-32-2)

Safety Data

• Hazardous Substances Data: 943995-32-2(Hazardous Substances Data)

Usage

Uses

2-Chloro-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one is a general reagent in pharmaceutical syntheses.

Upstream product

• 943995-31-1 4-amino-2-chloropyrimidin-5-ol 
• 79-04-9 chloroacetyl chloride 
• 105-36-2 ethyl bromoacetate 
• 99979-77-8 2-chloro-5-methoxypyrimidin-4-amine 

Downstream Products

• 1349829-86-2 2-((2R,5R)-2-methyl-5-phenylmorpholino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one 

Relevant articles and documents

Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists

A novel series of morpholine-based nonsteroidal mineralocorticoid receptor antagonists is reported. Starting from a pyrrolidine HTS hit 9 that possessed modest potency but excellect selectivity versus related nuclear hormone receptors, a series of libraries led to identification of morpholine lead 10. After further optimization, cis disubstituted morpholine 22 was discovered, which showed a 45-fold boost in binding affinity and corresponding functional potency compared to 13. While 22 had high clearance in rat, it provided sufficient exposure at high doses to favorably assess in vivo efficacy (increased urinary Na+/K+ ratio) and safety. In contrast to rat, the dog and human MetID and PK profiles of 22 were adequate, suggesting that it could be suitable as a potential clinical asset.

MORPHOLINE COMPOUNDS

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.